Influence of Multimorbidity on Burden and Appropriateness of Implantable Cardioverter-Defibrillator Therapies
- PMID: 30892695
- PMCID: PMC6743319
- DOI: 10.1111/jgs.15839
Influence of Multimorbidity on Burden and Appropriateness of Implantable Cardioverter-Defibrillator Therapies
Erratum in
-
Corrigendum.J Am Geriatr Soc. 2019 Nov;67(11):2430. doi: 10.1111/jgs.16175. Epub 2019 Sep 17. J Am Geriatr Soc. 2019. PMID: 31736070 No abstract available.
Abstract
Objective: To determine whether burden of multiple chronic conditions (MCCs) influences the risk of receiving inappropriate vs appropriate device therapies.
Design: Retrospective cohort study.
Setting: Seven US healthcare delivery systems.
Participants: Adults with left ventricular systolic dysfunction receiving an implantable cardioverter-defibrillator (ICD) for primary prevention.
Measurements: Data on 24 comorbid conditions were captured from electronic health records and categorized into quartiles of comorbidity burden (0-3, 4-5, 6-7 and 8-16). Incidence of ICD therapies (shock and antitachycardia pacing [ATP] therapies), including appropriateness, was collected for 3 years after implantation. Outcomes included time to first ICD therapy, total ICD therapy burden, and risk of inappropriate vs appropriate ICD therapy.
Results: Among 2235 patients (mean age = 69 ± 11 years, 75% men), the median number of comorbidities was 6 (interquartile range = 4-8), with 98% having at least two comorbidities. During a mean 2.2 years of follow-up, 18.3% of patients experienced at least one appropriate therapy and 9.9% experienced at least one inappropriate therapy. Higher comorbidity burden was associated with an increased risk of first inappropriate therapy (adjusted hazard ratio [HR] = 1.94 [95% confidence interval {CI} = 1.14-3.31] for 4-5 comorbidities; HR = 2.25 [95% CI = 1.25-4.05] for 6-7 comorbidities; and HR = 2.91 [95% CI = 1.54-5.50] for 8-16 comorbidities). Participants with 8-16 comorbidities had a higher total burden of ICD therapy (adjusted relative risk [RR] = 2.12 [95% CI = 1.43-3.16]), a higher burden of inappropriate therapy (RR = 3.39 [95% CI = 1.67-6.86]), and a higher risk of receiving inappropriate vs appropriate therapy (RR = 1.74 [95% CI = 1.07-2.82]). Comorbidity burden was not significantly associated with receipt of appropriate ICD therapies. Patterns were similar when separately examining shock or ATP therapies.
Conclusions: In primary prevention ICD recipients, MCC burden was independently associated with an increased risk of inappropriate but not appropriate device therapies. Comorbidity burden should be considered when engaging patients in shared decision making about ICD implantation.
Keywords: chronic disease; comorbidity; implantable cardioverter-defibrillator; multimorbidity; patient-centered outcomes.
© 2019 The American Geriatrics Society.
Figures
Similar articles
-
Kidney function and appropriateness of device therapies in adults with implantable cardioverter defibrillators.Heart. 2017 Apr;103(7):529-537. doi: 10.1136/heartjnl-2016-309842. Epub 2016 Oct 14. Heart. 2017. PMID: 27742796 Free PMC article.
-
Device Therapies Among Patients Receiving Primary Prevention Implantable Cardioverter-Defibrillators in the Cardiovascular Research Network.J Am Heart Assoc. 2018 Mar 26;7(7):e008292. doi: 10.1161/JAHA.117.008292. J Am Heart Assoc. 2018. PMID: 29581222 Free PMC article.
-
Benefit of Implantable Cardioverter-Defibrillator Generator Replacement in a Primary Prevention Population-Based Cohort.JACC Clin Electrophysiol. 2017 Oct;3(10):1180-1189. doi: 10.1016/j.jacep.2017.03.004. Epub 2017 May 31. JACC Clin Electrophysiol. 2017. PMID: 29759503
-
Association of Implantable Cardioverter Defibrillator Therapy with All-Cause Mortality-A Systematic Review and Meta-Analysis.Pacing Clin Electrophysiol. 2016 Jan;39(1):81-8. doi: 10.1111/pace.12766. Epub 2015 Nov 19. Pacing Clin Electrophysiol. 2016. PMID: 26470761 Review.
-
Impact of prolonged implantable cardioverter-defibrillator arrhythmia detection times on outcomes: a meta-analysis.Heart Rhythm. 2014 May;11(5):828-35. doi: 10.1016/j.hrthm.2014.02.009. Epub 2014 Feb 12. Heart Rhythm. 2014. PMID: 24530622 Review.
Cited by
-
Can the Norton Scale Score Be Used as an Adjunct Tool for Implantable Defibrillator Patient Selection? A Retrospective Single-Center Cohort Study.J Clin Med. 2022 Dec 27;12(1):214. doi: 10.3390/jcm12010214. J Clin Med. 2022. PMID: 36615015 Free PMC article.
-
Progression of infarct-mediated arrhythmogenesis in a rodent model of heart failure.Am J Physiol Heart Circ Physiol. 2021 Jan 1;320(1):H108-H116. doi: 10.1152/ajpheart.00639.2020. Epub 2020 Nov 8. Am J Physiol Heart Circ Physiol. 2021. PMID: 33164577 Free PMC article.
References
-
- Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346: 877–883. - PubMed
-
- Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352: 225–237. - PubMed
-
- Tung P, Albert CM. Causes and prevention of sudden cardiac death in the elderly. Nature reviews Cardiology. 2013;10: 135–142. - PubMed
-
- Peck KY, Lim YZ, Hopper I, Krum H. Medical therapy versus implantable cardioverter -defibrillator in preventing sudden cardiac death in patients with left ventricular systolic dysfunction and heart failure: a meta-analysis of > 35,000 patients. International journal of cardiology. 2014;173: 197–203. - PubMed
-
- Epstein AE, DiMarco JP, Ellenbogen KA, et al. 2012 ACCF/AHA/HRS focused update incorporated into the ACCF/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation. 2013;127: e283–352. - PubMed
Publication types
MeSH terms
Grants and funding
- American College of Cardiology Foundation/International
- 17MCPRP33370062/American Heart Association/International
- UL1 TR001863/TR/NCATS NIH HHS/United States
- U19HL091179/HL/NHLBI NIH HHS/United States
- R24AG045050/AG/NIA NIH HHS/United States
- T32AG019134/AG/NIA NIH HHS/United States
- T32 AG019134/AG/NIA NIH HHS/United States
- P30 AG021342/AG/NIA NIH HHS/United States
- 290-05-0033/Agency for Healthcare Research and Quality/International
- 17MCPRP33670631/American Heart Association/International
- U19 HL091179/HL/NHLBI NIH HHS/United States
- K07 AG043587/AG/NIA NIH HHS/United States
- R24 AG045050/AG/NIA NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
